Patient Treatment Planner

PM-GBL-CBR-WCNT-240030 March 2025

ARV=antiretroviral.

References:

  1. VOCABRIA (cabotegravir) 600 mg suspension for injection Summary of Product Characteristics (SmPC)
  2. VOCABRIA (cabotegravir) 30 mg film-coated tablets Summary of Product Characteristics (SmPC)
  3. REKAMBYS (rilpivirine) 900 mg suspension for injection Summary of Product Characteristics (SmPC)
  4. EDURANT (rilpivirine) 25 mg film-coated tablets Summary of Product Characteristics (SmPC).

EDURANT (rilpivirine), including the trademark, is owned by Janssen Pharmaceutical Companies. REKAMBYS (rilpivirine long-acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned or licensed by the ViiV Healthcare group.

PM-GB-CBR-WCNT-260002 March 2026

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.